Genmab A/S (GMAB)

業務介紹

根據提供的資訊,以下是英文內容的繁體中文翻譯:

Genmab A/S 主要在丹麥開發用於治療癌症和其他疾病的抗體療法。該公司銷售以下產品:

- DARZALEX,一種用於治療多發性骨髓瘤患者的人源化單克隆抗體
- teprotumumab,用於治療甲狀腺眼病
- ofatumumab,一種用於治療慢性淋巴細胞白血病和多發性硬化症的人源化單克隆抗體
- Amivantamab,用於治療晚期或轉移性胃癌、食道癌和非小細胞肺癌

該公司的其他產品包括:

- daratumumab,用於治療多發性骨髓瘤、非多發性骨髓瘤血液癌和AL淀粉樣變性
- GEN1047
- tisotumab vedotin,用於治療宮頸癌、卵巢癌和實體瘤
- DuoBody-PD-L1x4-1BB和DuoBody-CD40x4-1BB,用於治療實體瘤
- Epcoritamab,用於治療復發/難治性彌漫性大B細胞淋巴瘤和慢性淋巴細胞白血病
- HexaBody-CD38和DuoHexaBody-CD37,用於治療血液惡性腫瘤

該公司還在研發Teclistamab、Camidanlumab tesirine、JNJ-64007957、JNJ-64407564、PRV-015、Mim8和Lu AF82422等多種處於II期臨床試驗階段的產品。此外,該公司還有約20個正在進行前期臨床研究的項目。

Genmab A/S成立於1999年,總部位於丹麥哥本哈根。



Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

公司網址

https://www.genmab.com